These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33576872)

  • 21. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
    Jia XH; Geng LY; Jiang PP; Xu H; Nan KJ; Yao Y; Jiang LL; Sun H; Qin TJ; Guo H
    J Exp Clin Cancer Res; 2020 Dec; 39(1):284. PubMed ID: 33317597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
    Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen H; Wang D; Zhong Q; Tao Y; Zhou Y; Shi Y
    Cancer Immunol Immunother; 2020 Dec; 69(12):2413-2424. PubMed ID: 32749571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
    Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis.
    Nara K; Taguchi S; Buti S; Kawai T; Uemura Y; Yamamoto T; Kume H; Takada T
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic disease and adverse events from immune checkpoint inhibitors.
    Leiter A; Carroll E; De Alwis S; Brooks D; Shimol JB; Eisenberg E; Wisnivesky JP; Galsky MD; Gallagher EJ
    Eur J Endocrinol; 2021 Jun; 184(6):857-865. PubMed ID: 34552304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
    Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
    Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
    Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy.
    Yokohama K; Asai A; Matsui M; Okamoto N; Yasuoka H; Nishikawa T; Ohama H; Tsuchimoto Y; Inoue Y; Fukunishi S; Uchiyama K; Higuchi K
    Sci Rep; 2020 Sep; 10(1):14470. PubMed ID: 32879383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
    Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
    Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
    J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
    Morales-Barrera R; Villacampa G; Vidal N; Figols M; Giner J; Bonfill T; Suárez C; Díaz N; Mateo J; González M; Domenech M; Puente J; Carles J
    Clin Transl Oncol; 2023 Dec; 25(12):3556-3564. PubMed ID: 37217634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.